From the story, it actually sounds like it is making exclusivity LESS exclusive. Basically, if two companies are delivering the SAME gene but using different vectors then both get approved. This would theoretically result in more competition by not having to wait for the exclusivity (of the first approved) to end to enter the market.
News 
Market Data 
Discover 
